Adcirca
Phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH).
Currently, there are no issues on this topic.
Find more entities like Adcirca
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.